Imvotamab

[1]Hernandez G H, et al. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies[J]. Blood, 2022, 140 (Supplement 1) : 6436-6438.|[2]Li K, et al. Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile[J]. Blood, 2022, 140 (Supplement 1) : 6010-6011.|[3]Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136: 45-46.|[4]Hart K C, et al. High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing[J]. Cancer Research, 2022, 82 (12_Supplement) : 4179-4179.|[5]Baliga R, et al. A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release[J]. Cancer Res, 2020, 80 (16 Supplement) : 5664-5664.